CD80+ and CD86+B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis
Authors:
- Soraya Maria MenezesSMSoraya Maria Menezes
- Daniele DecanineDDDaniele Decanine
- David BrassatDBDavid Brassat
- Ricardo KhouriRKRicardo Khouri
- Saul V SchnitmanSSSaul V Schnitman
- Ramon KruschewskyRKRamon Kruschewsky
- Giovanni LópezGLGiovanni López
- Carolina AlvarezCACarolina Alvarez
- Michael TalledoMTMichael Talledo
- Eduardo GotuzzoEGEduardo Gotuzzo
- Anne-Mieke VandammeAVAnne-Mieke Vandamme
- Bernardo Galvão-CastroBGBernardo Galvão-Castro
Open Access
- 29 January 2014
- journal article
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 11 (1) , 18
Abstract
Background: Human T-cell lymphotropic virus (HTLV-1) is the causative agent of the incapacitating, neuroinflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Currently, there are no disease-modifying therapies with long-term clinical benefits or validated biomarkers for clinical follow-up in HAM/TSP. Although CD80 and CD86 costimulatory molecules play prominent roles in immune regulation and reflect disease status in multiple sclerosis (MS), data in HAM/TSP are lacking.Methods: Using flow cytometry, we quantifiedex vivoandin vitroexpression of CD80 and CD86 in PBMCs of healthy controls, HTLV-1-infected individuals with and without HAM/TSP, and MS patients. We hypothesizedex vivoCD80 and CD86 expressions and theirin vitroregulation by interferon (IFN)-α/β mirror similarities between HAM/TSP and MS and hence might reveal clinically useful biomarkers in HAM/TSP.Results: Ex vivoexpression of CD80 and CD86 in T and B cells increased in all HTLV-1 infected individuals, but with a selective defect for B cell CD86 upregulation in HAM/TSP. Despite decreased total B cells with increasing disease duration (p = 0.0003,r = −0.72), CD80+B cells positively correlated with disease severity (p = 0.0017,r = 0.69) in HAM/TSP. B cell CD80 expression was higher in women with HAM/TSP, underscoring that immune markers can reflect the female predominance observed in most autoimmune diseases. In contrast to MS patients, CD80+(p = 0.0001) and CD86+(p = 0.0054) lymphocytes expanded uponin vitroculture in HAM/TSP patients. The expansion of CD80+and CD86+T cells but not B cells was associated with increased proliferation in HTLV-1 infection.In vitrotreatment with IFN-β but not IFN-α resulted in a pronounced increase of B cell CD86 expression in healthy controls, as well as in patients with neuroinflammatory disease (HAM/TSP and MS), similar toin vivotreatment in MS.Conclusions: We propose two novel biomarkers,ex vivoCD80+B cells positively correlating to disease severity and CD86+B cells preferentially induced by IFN-β, which restores defective upregulation in HAM/TSP. This study suggests a role for B cells in HAM/TSP pathogenesis and opens avenues to B cell targeting (with proven clinical benefit in MS) in HAM/TSP but also CD80-directed immunotherapy, unprecedented in both HAM/TSP and MS.Keywords
This publication has 134 references indexed in Scilit:
- Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosisNature, 2011
- Reprogrammed quiescent B cells provide an effective cellular therapy against chronic experimental autoimmune encephalomyelitisEuropean Journal of Immunology, 2011
- A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cellsNature, 2010
- Treatment of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis: Toward Rational Targeted TherapyNeurologic Clinics, 2008
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Comparable potency of IFNα2 and IFNβ on immediate JAK/STAT activation but differential down-regulation of IFNAR2Biochemical Journal, 2007
- The IRF family, revisitedBiochimie, 2007
- Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patientsJournal of Neuroimmunology, 2006
- Activators and target genes of Rel/NF-κB transcription factorsOncogene, 1999
- Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphomaProceedings of the National Academy of Sciences, 1980